PMID- 35345273
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20220418
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 23
IP  - 3
DP  - 2022 Mar 17
TI  - Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The 
      Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
PG  - 106
LID - 10.31083/j.rcm2303106 [doi]
AB  - Type 2 Diabetes Mellitus (T2DM) is associated with an elevated incidence of 
      cardiovascular and renal diseases, responsible for mortality rates significantly 
      higher than in the general population. The management of both cardiovascular risk 
      and progression of kidney disease thus seem crucial in the treatment of the 
      diabetic patient. The availability of new classes of drugs which positively 
      affect both cardiovascular and renal risk, regardless of the glycemic control, 
      represents a revolution in the treatment of T2DM and shifts the attention from 
      the intensive glycemic control to a holistic management of the diabetic patient. 
      Among these, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been 
      associated with a remarkable reduction of cardiovascular and renal mortality, 
      lower hospitalization rates for heart failure and lower progression of renal 
      damage and albuminuria. Thus, their use in selected subpopulations seems 
      mandatory. Aim of this review was the assessment of the current evidence on 
      SGLT2i and their related impact on the cardiovascular and renal profiles.
CI  - (c) 2022 The Author(s). Published by IMR Press.
FAU - Nevola, Riccardo
AU  - Nevola R
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
AD  - Department of Internal Medicine, Betania Evangelical Hospital, Via Argine, 80147 
      Naples, Italy.
FAU - Alfano, Maria
AU  - Alfano M
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
FAU - Pafundi, Pia Clara
AU  - Pafundi PC
AD  - Facility of Epidemiology and Biostatistics, Gemelli Generator, Fondazione 
      Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
FAU - Brin, Chiara
AU  - Brin C
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
FAU - Gragnano, Felice
AU  - Gragnano F
AD  - Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
AD  - Department of Translational Medical Sciences, University of Campania "Luigi 
      Vanvitelli", 80138 Naples, Italy.
FAU - Calabro, Paolo
AU  - Calabro P
AD  - Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
AD  - Department of Translational Medical Sciences, University of Campania "Luigi 
      Vanvitelli", 80138 Naples, Italy.
FAU - Adinolfi, Luigi Elio
AU  - Adinolfi LE
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
FAU - Rinaldi, Luca
AU  - Rinaldi L
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
FAU - Sasso, Ferdinando Carlo
AU  - Sasso FC
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
FAU - Caturano, Alfredo
AU  - Caturano A
AD  - Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, 
      University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - Female
MH  - *Heart Failure/diagnosis/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Male
MH  - *Renal Insufficiency, Chronic/diagnosis/epidemiology
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
OTO - NOTNLM
OT  - SGLT2i
OT  - chronic kidney disease
OT  - diabetes
OT  - gliflozin
OT  - heart failure
COIS- The authors declare no conflict of interest. Ferdinando Carlo Sasso is serving as 
      one of the Editorial Board members of this journal. We declare that Ferdinando 
      Carlo Sasso had no involvement in the peer review of this article and has no 
      access to information regarding its peer review. Full responsibility for the 
      editorial process for this article was delegated to Massimo Volpe, Filippos 
      Triposkiadis, Grigorios Korosoglou and Matteo Cameli.
EDAT- 2022/03/30 06:00
MHDA- 2022/04/19 06:00
CRDT- 2022/03/29 01:40
PHST- 2021/12/02 00:00 [received]
PHST- 2022/01/01 00:00 [revised]
PHST- 2022/01/06 00:00 [accepted]
PHST- 2022/03/29 01:40 [entrez]
PHST- 2022/03/30 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
AID - S1530-6550(22)00430-6 [pii]
AID - 10.31083/j.rcm2303106 [doi]
PST - ppublish
SO  - Rev Cardiovasc Med. 2022 Mar 17;23(3):106. doi: 10.31083/j.rcm2303106.